Microbiology and Preclinical Review of Omadacycline

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
James A KarlowskyGeorge G Zhanel

Abstract

Omadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, vancomycin-resistant Enterococcus, and Enterobacteriaceae. Omadacycline is also active against atypical and anaerobic pathogens, including Legionella pneumophila, Mycoplasma spp., Ureaplasma spp., Bacteroides spp., and Clostridioides difficile. This review outlines the microbiology and preclinical studies of omadacycline, including its mechanism of action; spectrum of activity; protein binding; activity in the presence of surfactant, serum, normal, and pH-adjusted urine, or bacterial biofilms; postantibiotic effect; pharmacodynamic properties; and in vitro and in vivo efficacy. The results of in vitro and in vivo animal studies support the observations made in phase III clinical trials and the clinical development of omadacycline.

References

Jun 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L ReimerS Mirrett
Jul 1, 1996·Diagnostic Microbiology and Infectious Disease·J SegretiK Kapell
Feb 3, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B FacinelliP E Varaldo
Apr 30, 2005·The Journal of Antimicrobial Chemotherapy·Simon D BainesMark H Wilcox
Apr 8, 2006·Letters in Applied Microbiology·Y Rukayadi, J-K Hwang
Jul 4, 2006·The Journal of Antimicrobial Chemotherapy·Kenneth N Agwuh, Alasdair MacGowan
Feb 13, 2008·Journal of Environmental Quality·Keith A LoftinRao Surampalli
Mar 30, 2010·Journal of Pain & Palliative Care Pharmacotherapy· U S Food And Drug Administration
May 25, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S P Hawser
Nov 19, 2011·The International Journal of Artificial Organs·Jeffrey B Kaplan
Dec 14, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C SilvestriA Giacometti
May 22, 2013·International Journal of Antimicrobial Agents·Tomasz A LeskiGary J Vora
Sep 18, 2013·Antimicrobial Agents and Chemotherapy·Michael P DraperStuart B Levy
Dec 4, 2013·Antimicrobial Agents and Chemotherapy·A B MaconeS B Levy
Jun 4, 2015·FEMS Microbiology Ecology·Sudeshna GhoshMichael J Sadowsky
Jul 30, 2016·Bioorganic & Medicinal Chemistry·S Ken TanakaStephen Villano
Aug 9, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jimmy FlarakosJames B Mangold
Feb 15, 2017·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Feb 23, 2017·Antimicrobial Agents and Chemotherapy·Judith SteenbergenJeremy R Hershfield
Nov 22, 2017·Diagnostic Microbiology and Infectious Disease·M A PfallerR K Flamm
Feb 6, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Raseen TariqSahil Khanna
Feb 15, 2018·Antimicrobial Agents and Chemotherapy·Laure StapertChris Pillar
Feb 7, 2019·The New England Journal of Medicine·William O'RiordanEvan Loh
Feb 7, 2019·The New England Journal of Medicine·Roman StetsEvan Loh
Mar 13, 2019·Antimicrobial Agents and Chemotherapy·Carolyn ShoenMichael Cynamon
Jun 5, 2019·Antimicrobial Agents and Chemotherapy·Stephan KohlhoffMargaret R Hammerschlag

❮ Previous
Next ❯

Citations

Aug 2, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason C Gallagher
Oct 16, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Miguel G Madariaga
Nov 13, 2019·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Nov 28, 2019·Clinical Pharmacokinetics·Keith A RodvoldManjunath P Pai
May 2, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Dong DongFupin Hu
Jun 10, 2020·Antimicrobial Agents and Chemotherapy·Khurshida BegumKevin W Garey
May 21, 2020·Surgical Infections·Paul M RobbenRoseanne A Ressner
Jan 24, 2020·Drugs·George G ZhanelJames A Karlowsky
Dec 10, 2020·The Journal of Antimicrobial Chemotherapy·A R NoelA P MacGowan
Dec 9, 2020·Antimicrobial Agents and Chemotherapy·Barbara A Brown-Elliott, Richard J Wallace
Feb 18, 2021·Expert Review of Anti-infective Therapy·Alessandro RussoMatteo Bassetti
Apr 4, 2021·Microorganisms·Corneliu Ovidiu VrancianuMariana Carmen Chifiriuc
May 12, 2021·Antimicrobial Agents and Chemotherapy·Kavindra V Singh, Barbara E Murray
Jun 15, 2021·Antimicrobial Agents and Chemotherapy·Kavindra V SinghBarbara E Murray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.